Opus Genetics Overview
- Year Founded
-
2018
- Status
-
Public
- Employees
-
14
- Stock Symbol
-
IRD
- Investments
-
3
- Share Price
-
$1.03
- (As of Wednesday Closing)
Opus Genetics General Information
Description
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
Contact Information
Website
www.ocuphire.comCorporate Office
- 37000 Grand River Avenue
- Suite 120
- Farmington Hills, MI 48335
- United States
Corporate Office
- 37000 Grand River Avenue
- Suite 120
- Farmington Hills, MI 48335
- United States
Opus Genetics Stock Performance
As of 26-Mar-2025, Opus Genetics’s stock price is $1.03. Its current market cap is $46.3M with 45M shares.
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.03 | $1.13 | $0.81 - $2.34 | $46.3M | 45M | 220K | -$1.09 |
Opus Genetics Financials Summary
As of 30-Sep-2024, Opus Genetics has a trailing 12-month revenue of $8.38M.
|
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | (7,094) | 25,778 | 59,493 | 41,898 |
| Revenue | 8,381 | 19,049 | 39,850 | 589 |
| EBITDA | (28,519) | (9,968) | 18,216 | (56,687) |
| Net Income | (27,192) | (9,986) | 17,888 | (56,693) |
| Total Assets | 40,389 | 53,948 | 48,992 | 26,077 |
| Total Debt | 0 | 0 | 0 | 538 |
Opus Genetics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Opus Genetics Comparisons
Industry
Financing
Details
Opus Genetics Competitors (13)
One of Opus Genetics’s 13 competitors is Exonate, a Venture Capital-Backed company based in Cambridge, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Exonate | Venture Capital-Backed | Cambridge, United Kingdom | ||||
| Genentech | Formerly VC-backed | South San Francisco, CA | ||||
| ONL Therapeutics | Venture Capital-Backed | Ann Arbor, MI | ||||
| Oxurion | Corporation | Leuven, Belgium | ||||
| EyePoint Pharmaceuticals | Corporation | Watertown, MA |
Opus Genetics Patents
Opus Genetics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2014221841-A | Ophthalmic formulations including selective α1 antagonists | Pending | 14-Jun-2004 | ||
| JP-2012036217-A | Ophthalmic formulation including selective α1 antagonist | Pending | 14-Jun-2004 | ||
| CA-2569468-C | Ophthalmic formulations including selective alpha 1 antagonists | Inactive | 14-Jun-2004 | ||
| CA-2569468-A1 | Ophthalmic formulations including selective alpha 1 antagonists | Active | 14-Jun-2004 | ||
| EP-1755591-A2 | Ophthalmic formulations including selective alpha 1 antagonists | Inactive | 14-Jun-2004 | A61K9/0048 |
Opus Genetics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Opus Genetics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Opus Genetics Acquisitions (3)
Opus Genetics’s most recent deal was a Merger/Acquisition with Opus Genetics (acquired in 2024)). The deal was made on 22-Oct-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Opus Genetics (acquired in 2024)) | 22-Oct-2024 | Merger/Acquisition | Drug Discovery | ||
| Rexahn Pharmaceuticals | 05-Nov-2020 | Merger/Acquisition | Drug Discovery | ||
| Ocularis | 01-Jan-2018 | Merger/Acquisition | Pharmaceuticals |
Opus Genetics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Opus Genetics Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Opus Genetics (acquired in 2024)) | Durham, NC | 2021 |
Opus Genetics FAQs
-
When was Opus Genetics founded?
Opus Genetics was founded in 2018.
-
Where is Opus Genetics headquartered?
Opus Genetics is headquartered in Farmington Hills, MI.
-
What is the size of Opus Genetics?
Opus Genetics has 14 total employees.
-
What industry is Opus Genetics in?
Opus Genetics’s primary industry is Pharmaceuticals.
-
Is Opus Genetics a private or public company?
Opus Genetics is a Public company.
-
What is Opus Genetics’s stock symbol?
The ticker symbol for Opus Genetics is IRD.
-
What is the current stock price of Opus Genetics?
As of 26-Mar-2025 the stock price of Opus Genetics is $1.03.
-
What is the current market cap of Opus Genetics?
The current market capitalization of Opus Genetics is $46.3M.
-
What is Opus Genetics’s current revenue?
The trailing twelve month revenue for Opus Genetics is $8.38M.
-
Who are Opus Genetics’s competitors?
Exonate, Genentech, ONL Therapeutics, Oxurion, and EyePoint Pharmaceuticals are some of the 13 competitors of Opus Genetics.
-
What is Opus Genetics’s annual earnings per share (EPS)?
Opus Genetics’s EPS for 12 months was -$1.09.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
